Acelyrin, Inc. (NASDAQ:SLRN - Get Free Report)'s stock price reached a new 52-week low during trading on Wednesday . The company traded as low as $5.61 and last traded at $5.67, with a volume of 81890 shares. The stock had previously closed at $5.95.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently issued reports on SLRN shares. Wells Fargo & Company boosted their price objective on Acelyrin from $11.00 to $13.00 and gave the company an "equal weight" rating in a research note on Thursday, March 21st. HC Wainwright reissued a "buy" rating and issued a $28.00 price target on shares of Acelyrin in a research note on Monday, April 1st. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $23.67.
Check Out Our Latest Stock Analysis on SLRN
Acelyrin Stock Down 4.2 %
The stock has a market cap of $560.65 million and a PE ratio of -0.53. The business's 50-day simple moving average is $7.62 and its 200-day simple moving average is $8.02.
Insider Buying and Selling
In other news, CEO Shao-Lee Lin sold 15,701 shares of Acelyrin stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $7.60, for a total value of $119,327.60. Following the sale, the chief executive officer now directly owns 1,587,335 shares in the company, valued at approximately $12,063,746. The sale was disclosed in a filing with the SEC, which is available through this link.
Institutional Trading of Acelyrin
Large investors have recently bought and sold shares of the company. Vanguard Group Inc. raised its position in shares of Acelyrin by 93.0% in the 4th quarter. Vanguard Group Inc. now owns 6,155,910 shares of the company's stock worth $45,923,000 after acquiring an additional 2,966,883 shares in the last quarter. Blue Owl Capital Holdings LP bought a new position in Acelyrin in the fourth quarter worth $17,106,000. Virtus ETF Advisers LLC purchased a new position in Acelyrin during the fourth quarter valued at $95,000. Voloridge Investment Management LLC bought a new stake in shares of Acelyrin during the 4th quarter valued at $773,000. Finally, Nuveen Asset Management LLC boosted its holdings in shares of Acelyrin by 50.8% during the 4th quarter. Nuveen Asset Management LLC now owns 67,771 shares of the company's stock valued at $506,000 after buying an additional 22,835 shares in the last quarter. 87.31% of the stock is owned by institutional investors.
About Acelyrin
(
Get Free Report)
Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.
Featured Stories
Before you consider Acelyrin, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Acelyrin wasn't on the list.
While Acelyrin currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
